Clinical trials: Colon Cancer
Relapse, Advanced Malignant Neoplasm
A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies
A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR106 in Patients with Select Relapsed Advanced Malignancies (JIVAN).
- Conditions
- Relapse, Advanced Malignant Neoplasm, Non Small Cell Lung Cancer, Gastric Cancer
- Trial name
- JIVAN (NCT05861947)
- Testing
- AUR106
- Where
- 6 sites in India
- Volunteers
- 21 people
- Sponsor
- Aurigene Discovery Technologies Limited
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer Metastatic, Adenocarcinoma of Colon
Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer
This Phase 1/2 study evaluates the safety, tolerability, and preliminary anti-tumor activity of an allogeneic dual-target chimeric antigen receptor natural killer (CAR-NK) cell product in adults with advanced or metastatic…
- Trial name
- NCT07462650
- Testing
- EB-DUO-CAR-NK-CEA/GCC (IV)
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Beijing Biotech
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer
- Trial name
- NCT06625515
- Testing
- ATX-559
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Accent Therapeutics
Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
A clinical trial to assess the safety and efficacy of genetically-engineered, neoantigen-specific Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing…
- Conditions
- Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract, Cancer, Gastrointestinal
- Trial name
- NCT04426669
- Testing
- Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Intima Bioscience, Inc.
Colorectal Cancer, Metastatic Colon Cancer
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
The purpose of this study is to measure tumor response to treatment with ompenaclid (RGX-202-01) in patients with previously treated RAS mutant advanced or metastatic CRC.
- Trial name
- NCT05983367
- Testing
- Ompenaclid, Bevacizumab, FOLFIRI regimen
- Where
- 28 sites in Belgium, France and 1 more
- Volunteers
- 76 people
- Sponsor
- Inspirna, Inc.
Stage II Colon Cancer
A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer
OncoVAX® is the first cancer therapy that both prevents cancer recurrence and addresses the diversity of cancer cells. In this pivotal randomized, multicenter Phase IIIb study in patients with Stage II colon cancer, OncoVAX is…
- Trial name
- NCT02448173
- Testing
- OncoVAX and Surgery, Surgery
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Vaccinogen Inc
Neoplasms, Colorectal, Solid Tumor
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat.
- Conditions
- Neoplasms, Colorectal, Solid Tumor, Colon Cancer, Rectal Cancer
- Trial name
- SYLVER (NCT06710847)
- Testing
- GSK4418959, PD-1 inhibitor
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 14 people
- Sponsor
- GlaxoSmithKline
Lung Cancer, Colon Cancer
A Study of PHN-010 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
- Conditions
- Lung Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT06457997
- Testing
- PHN-010
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Pheon Therapeutics
Colonic Neoplasms, Neoplasms, Colon
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
The primary purpose of this study is to evaluate the efficacy of perioperative dostarlimab compared with standard of care (SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/…
- Trial name
- NCT05855200
- Testing
- Dostarlimab, CAPEOX, FOLFOX
- Where
- 266 sites in United States, Argentina and 26 more
- Volunteers
- 892 people
- Sponsor
- GlaxoSmithKline
Colon Cancer Adenocarcinoma
A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer
This study is a phase Ib/II study to evaluate the efficacy, safety and tolerance of HLX43 combined with HLX07 or Serplulimab in patients with advanced or metastatic colorectal cancer failed or intolerance to standard first-line…
- Trial name
- NCT07358585
- Testing
- HLX43 dose 1 + HLX07, HLX43 dose 2 + HLX07, HLX43 dose 3 + Serplulimab
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Shanghai Henlius Biotech
Colorectal Cancer (CRC), Colon Cancer Liver Metastases
Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases
The goal of this clinical trial is to learn if a new injectable drug (IP-001), administered after standard liver tumor ablation, can help prevent cancer from returning in people (males/females, ≥18 years old) with colorectal…
- Conditions
- Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer, Rectal Cancer With Liver Metastases
- Trial name
- INJECTABL-3 (NCT07321847)
- Testing
- 1.0% IP-001 for Injection, a 10 mg/mL solution of IP-001 in water, 1.0% IP-001 for Injection, a 1 mg/mL solution of IP-001 in water., Microwave (thermal) tumor ablation
- Volunteers
- 717 people
- Sponsor
- Immunophotonics, Inc.
Solid Tumor, Colon Carcinoma
PET-imaging of Two Vartumabs in Patients With Solid Tumors
VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS).
- Conditions
- Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma
- Trial name
- VARTUTRACE (NCT06645808)
- Testing
- 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Var2 Pharmaceuticals
Colon Cancer, Rectal Cancer
Prevention of Colorectal Cancer Through Multiomics Blood Testing
The PREEMPT CRC study is a prospective multi-center observational study to validate a blood-based test for the early detection of colorectal cancer by collecting blood samples from average-risk participants who will undergo a…
- Conditions
- Colon Cancer, Rectal Cancer, Colon Neoplasm, Colon Diseases
- Trial name
- PREEMPT CRC (NCT04369053)
- Testing
- Freenome test
- Where
- 148 sites in United States, Canada
- Volunteers
- 48,995 people, healthy volunteers welcome
- Sponsor
- Freenome Holdings Inc.
Colon Cancer
A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
The goal of this clinical trial is to evaluate the efficacy of neoadjuvant QL1706 in participants with untreated T4N0 or Stage III (resectable), microsatellite instability high/ defective mismatch repair (MSI-H/dMMR) colon cancer
- Trial name
- NCT06686576
- Testing
- QL1706, CAPEOX/Capecitabine
- Where
- China
- Volunteers
- 363 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Solid Tumor Cancer, Adult Refractory Cancer
Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
- Conditions
- Solid Tumor Cancer, Adult Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma
- Trial name
- NCT07070518
- Testing
- GV20-0251
- Where
- 3 sites in China
- Volunteers
- 350 people
- Sponsor
- GV20 Therapeutics
Solid Tumor, Breast Tumor
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
- Conditions
- Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor
- Trial name
- PAVO (NCT05169437)
- Testing
- Niraparib
- Where
- 80 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tempus AI
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Colon Cancer
Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality
The purpose of this study is to gather information about the long term health of people who have been prescribed the Cologuard test, which is used for colorectal cancer (CRC) screening.
- Trial name
- NCT04124406
- Testing
- Cologuard
- Where
- United States
- Volunteers
- 150,000 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Screening for Colon Cancer, Survey and Questionnaire
Exploring Participant Preference for Screening Methods and Experience Into Colorectal Cancer Screening Programme
The goal of this low-risk interventional study is to analyze participants' assessment of colorectal cancer screening program through screening method preference and experience after FOBT analysis in screaned participant…
- Trial name
- MS-Care (NCT06696534)
- Testing
- Survey using a questionnaire.
- Where
- 2 sites in Portugal, Spain
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- ADVANCED MARKER DISCOVERY S.L.